RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

Learn more about how RYTELO (imetelstat) may work for lower-risk myelodysplastic syndromes (MDS) patients with transfusion-dependent anemia. See safety information, including thrombocytopenia, neutropenia, infusion-related reactions, and embryo-fetal toxicity.

Rytelo – uniquely positioned to address unmet need in LR- MDS. Rytelois an FDA approved (June 2024), first-in-class telomerase inhibitor to treat lower-risk myelodysplastic syndromes (LR - MDS) with TD anemia. LR-MDS is a progressive form of blood cancer where anemia and red blood cell (RBC) transfusion dependence drive high patient symptom ...

Mar 15, 2025 · Rytelo™ (imetelstat) is a first-in-class telomerase inhibitor approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia.

Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. [1] Imetelstat is an oligonucleotide telomerase inhibitor.

Drug Identifier results for "Rytelo". Search by imprint, shape, color or drug name.

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

Jul 16, 2024 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. Rytelo offers the potential for more than 24 weeks of freedom from red blood cell transfusions or anemia symptoms.

Rytelo™ (imetelstat) – New orphan drug approval • On June 6, 2024, the FDA announced the approval of Geron’s Rytelo (imetelstat), for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not

Jun 17, 2024 · Imetelstat is a telomerase inhibitor. Telomerase inhibitors work by targeting the telomerase enzyme to stop uncontrolled cell division and do not grow. This is helpful in treating conditions like myelodysplastic syndrome (MDS). Imetelstat is given intravenously (into a vein). The amount given and schedule are based on your size.